Lymphoma is a cancer of the immune system's B-lymphocytes. In Dr. Naidu's case it has grown in the wall of the small intestine (ileum) and the surrounding mesentery rather than in lymph nodes — this is called primary gastrointestinal, or extranodal, lymphoma.
The essential thing to hold on to: DLBCL is aggressive, but it is one of the most treatable cancers there is, and it is treated with the intention to cure, not merely control.
What every report found
Four investigations built this picture: a PET-CT scan to map the disease, a biopsy with immunohistochemistry to name it, a FISH test to check its genes, and an echocardiogram plus bloods to check he could withstand treatment.
Where the disease is — PET-CT, 7 July
What it is — biopsy & immunohistochemistry, 13 July
Pathologists stain the tumour cells for specific proteins. Each is a yes/no clue; together they name the disease precisely.
| Marker | Result | What it tells us |
|---|---|---|
| CD20 | Positive | Confirms a B-cell lymphoma — and CD20 is the exact target of rituximab, one of his drugs |
| CKit | Negative | Rules out GIST — settles the original "GIST vs lymphoma" question definitively |
| CD10 | Negative | Together, this pattern defines the non-germinal-centre (non-GCB) subtype |
| MUM1 | Positive | |
| BCL6 · BCL2 | Positive | BCL2 with c-Myc makes this a "double-expressor" at protein level |
| CD3 | Background only | Confirms the tumour is B-cell, not T-cell (T-cell bowel lymphomas do far worse — this is not that) |
| CyclinD1 · CD30 · AE1/AE3 | Negative | Excludes mantle cell and other look-alikes |
| Ki-67 (MIB1) | 70% | High proliferation — grows fast, but also responds fast to chemotherapy |
| c-Myc | 40–50% | Double-expressor feature — prompted the FISH test below |
The genes — FISH test, 17 July
MYC: negative. All 50 tumour cells showed fused signals — no rearrangement. BCL2: negative (10%, below the 15% threshold).
This matters a great deal. "Double-hit" lymphoma is a more aggressive entity that would have required intensified treatment and carried a poorer outlook. Dr. Naidu does not have it. He is a double-expressor at the protein level only — a milder, moderately adverse feature — and stays in the standard, more favourable DLBCL group.
Can he withstand treatment — heart & bloods
The biggest fear going in was that his prior heart attack would force a weaker, heart-sparing chemotherapy and cost him cure odds. His echocardiogram settled it: normal ejection fraction, no scarred muscle. He can receive the full, most effective regimen. His heart did not force a compromise.
Pola-R-CHP — six cycles
Five drugs, given together as an infusion, once every three weeks, six times. About four to five months from start to finish.
This is a modern, evidence-based choice. In the POLARIX trial, Pola-R-CHP improved outcomes over the older standard (R-CHOP), and the benefit was most pronounced in exactly Dr. Naidu's group: higher-risk, non-GCB DLBCL. His team selected it deliberately.
Every cycle follows the same shape: infusion day, then a dip, then a recovery. The hardest stretch is usually days 3–10, when blood counts fall and fatigue peaks. Then he climbs back up and generally feels closest to himself in the week before the next cycle. Knowing this pattern makes it far easier to bear — the bad days are expected and they end.
The six cycles, mapped
An interim PET (usually around cycle 3–4) checks that the lymphoma is melting away as it should. The end-of-treatment PET, several weeks after cycle 6, is the one that determines remission. His very high baseline SUV values are actually helpful here — they give a clear, measurable starting point to compare against.
Alongside the chemotherapy
- Anti-nausea medicines before and after each infusion — modern ones are very effective
- Blood tests before every cycle to confirm counts have recovered enough to proceed
- Cardiac monitoring — repeat echocardiograms during treatment, given the doxorubicin and his history
- Bowel monitoring, especially cycles 1–2, as the tumour shrinks
- His existing medicines continue — thyroid, and the heart/stent medicines, with the blood thinner plan agreed between cardiology and oncology
- G-CSF injections may be added if white counts drop too low
Where he is on the road
Managing each symptom, cycle by cycle
Most side effects are predictable, temporary, and manageable — especially when you know they're coming. Here is each one, what to expect, and what actually helps.
- The most universal effect. Deepest in the days after each infusion, building slowly across cycles.
- It is not ordinary tiredness — rest doesn't fully fix it. That's normal, not a bad sign.
- Short gentle walks — counterintuitive but genuinely evidence-backed. Even 10 minutes helps more than complete rest.
- Plan around the rhythm — schedule visitors and outings for days 12–21, when he'll feel most himself
- Naps under an hour, so night sleep isn't disrupted
- Let him do what he can, and let go of what he can't — without guilt on either side
- Modern anti-nausea medicines are very good — most people are far less sick than they fear.
- Taste changes are common; food may taste metallic or bland.
- Take the anti-nausea medicine on schedule, not only when he already feels sick — prevention works far better than rescue
- Small frequent meals rather than three large ones
- Bland, soft, warm foods on bad days: khichdi, dal-rice, curd (when allowed), toast, soups
- Cold or room-temperature food has less smell and is often easier
- Ginger or jeera water, and eating slowly
- Keeping fluids up matters more than eating perfectly
- White cells fall about a week after each infusion. This is the single most important risk in the whole treatment.
- He may feel perfectly fine during this window — that's the trap.
- Handwashing, by him and everyone around him
- No visitors with any cough, cold or fever — be firm about this, it isn't rude
- Avoid crowds and crowded transport during days 7–14
- Freshly cooked, hot food. No raw salads, no street food, no leftovers
- Daily bath, clean clothes, careful mouth care with a soft brush
- Salt-water or bicarbonate rinses several times daily — simple and effective
- Soft toothbrush; avoid alcohol-based mouthwash
- Avoid spicy, acidic, very hot or rough foods when sore
- Keep the mouth moist — sips of water, ice chips
- Polatuzumab can cause tingling or numbness in fingers and toes. It builds gradually and often improves after treatment ends.
- Report it early and at every visit — this is important. Doses can be adjusted before it becomes lasting
- Careful with hot pans, hot water, sharp objects — reduced sensation means burns and cuts go unnoticed
- Well-fitting shoes; watch footing on stairs
- Doxorubicin can affect heart function, and he starts with a prior heart attack, a stent and mild diastolic dysfunction. His echo cleared him, and the team will monitor throughout.
- Never stop the blood thinner without cardiology — and no ibuprofen or aspirin-type painkillers
- Weigh him regularly, same scale, same time — a rise over ~1kg/day suggests fluid building up
- Watch for ankle swelling and breathlessness lying flat
- Keep the agreed fluid target — enough to protect the kidneys, not so much it loads the heart
- Prednisone reliably pushes blood sugar up — expected, not alarming. It also causes restlessness and poor sleep for a few days, then settles.
- Check sugar regularly in the days after each infusion and write the numbers down
- No sugar, sweets or sweetened drinks during steroid days; small frequent meals
- Never adjust any medicine yourself — report the numbers and let the team decide
- Expect a few restless nights; the steroid stops and sleep returns
- His tumour sits in the bowel wall. As it shrinks — fastest in the first cycles — the team watches for bleeding or perforation. This is a known, monitored risk, not an expected event.
- The encouraging flip side: as the tumour shrinks, his pain and difficulty eating should improve.
- Soft, well-cooked, small frequent meals while eating is uncomfortable
- Track pain, gas and stool — a written record spots changes far better than memory
- No laxatives or enemas without asking
- Expected with this regimen, and temporary. Regrowth usually begins within a couple of months of finishing.
- Cutting it short early gives some sense of control and makes the change less jarring.
- Scalp gets sensitive — soft caps, sun protection.
- Low days are normal and not a failure of attitude. Steroids can swing mood sharply for a few days each cycle.
- The middle cycles are often hardest psychologically — the novelty has gone, the end still feels far.
- Mark each completed cycle. Six is finite. Crossing them off matters more than it sounds
- Keep some normal life in the calendar — a favourite meal, a film, people who don't only talk about cancer
- Let him have bad days without needing to be brave
- Tell the team about persistent low mood — it's common and treatable, not a weakness
Get help immediately for these
- Fever 38°C / 100.4°F or above — the most important one during chemotherapy
- Severe or worsening belly pain, hard belly, no gas or stool, repeated vomiting
- Chest pain or new breathlessness — given his heart, always
- Black or bloody stool, vomiting blood, unusual bruising — he is on a blood thinner
- Passing very little urine, or confusion, drowsiness, fainting
- Any infusion reaction — rash, breathing difficulty, swelling
- Uncontrolled vomiting or inability to keep fluids down
When you call, say this: "63-year-old man, diffuse large B-cell lymphoma with a tumour in the bowel wall, on Pola-R-CHP chemotherapy, has a coronary stent and takes clopidogrel."
Temperature, pain score, whether he passed gas and stool, roughly how much he drank, blood sugar, and how he seems. When something changes, precise information — "pain went from 3 to 7 at 2am, no gas since evening" — lets the team act fast. This is one of the most useful things a family can do.
What's genuinely in his favour
It is worth stepping back and seeing how much has gone right, because in the middle of treatment it is easy to lose sight of.
This is a serious cancer and the next few months will be demanding — there is no point pretending otherwise. But nearly every fork in the road so far has turned the favourable way: the GIST fear resolved into a treatable lymphoma, the T-cell fear resolved into B-cell, the double-hit fear resolved into negative, the heart cleared, and the disease turned out to be confined to one region. He is receiving a modern regimen chosen specifically for his subtype, at India's leading cancer centre, under a specialist in exactly this disease.
Six cycles is finite. There is a defined end to this, and the treatment is aimed at getting him back to his life.
Two things worth saying plainly. First: the most valuable thing you can do is notice things early and report them clearly. You do not need to be his doctor — the team carries the clinical weight. Your job is to be his eyes, his record-keeper, and his company.
Second: look after yourselves too. Caring for someone through months of chemotherapy is a long road. Share the load, take shifts, sleep. Dr. Naidu will need you across all six cycles and the recovery beyond — you cannot do that running on empty.